Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 20/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.54 |
| ▸ | MTOR | P42345 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30203933 | 1.00 | TGFBR1 (1.00) | TGFBR1MAPK14MTOR | |
| SCHEMBL30203968 | 0.94 | TGFBR1 (1.00) | TGFBR1MAPK14MTOR | |
| SCHEMBL14576531 | 0.94 | TGFBR1 (1.00) | TGFBR1MAPK14MTOR | |
| SCHEMBL14576260 | 0.90 | TGFBR1 (0.89) | TGFBR1MAPK14 | |
| SCHEMBL30204089 | 0.90 | TGFBR1 (0.89) | TGFBR1MAPK14 | |
| SCHEMBL14577024 | 0.83 | TGFBR1 (1.00) | TGFBR1MAPK14 | |
| SCHEMBL30203913 | 0.83 | TGFBR1 (1.00) | TGFBR1MAPK14 | |
| SCHEMBL21277970 | 0.82 | TGFBR1 (0.70) | TGFBR1MAPK14MTOR | |
| SCHEMBL26664562 | 0.81 | TGFBR1 (0.77) | TGFBR1MAPK14MTOR | |
| SCHEMBL26664554 | 0.81 | TGFBR1 (0.77) | TGFBR1MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10155763-B2 | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | TIUMBIO CO., LTD. (KR) | 2018-12-18 | — | — | US | claimed |
| EP-2731949-B1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS | TIUMBIO CO LTD (KR) | 2018-04-04 | — | — | EP | claimed |
| EP-2731949-A2 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS | SK Chemicals Co., Ltd. (KR) | 2014-05-21 | — | — | EP | claimed |
| WO-2013009140-A2 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS | SK CHEMICALS CO., LTD. (KR) | 2013-01-17 | — | — | WO | claimed |
| US-20130018052-A1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS | SK CHEMICALS CO., LTD. (KR) | 2013-01-17 | — | — | US | claimed |
| US-10155763-B2 | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | TIUMBIO CO., LTD. (KR) | 2018-12-18 | — | — | US | disclosed |
| EP-2731949-B1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS | TIUMBIO CO LTD (KR) | 2018-04-04 | — | — | EP | disclosed |
| EP-2731949-B1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS | TIUMBIO CO LTD (KR) | 2018-04-04 | — | — | EP | disclosed |
| EP-2731949-A2 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS | SK Chemicals Co., Ltd. (KR) | 2014-05-21 | — | — | EP | disclosed |
| US-20130018052-A1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS | SK CHEMICALS CO., LTD. (KR) | 2013-01-17 | — | — | US | disclosed |
| WO-2013009140-A2 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS | SK CHEMICALS CO., LTD. (KR) | 2013-01-17 | — | — | WO | disclosed |
| US-20130018052-A1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS | SK CHEMICALS CO., LTD. (KR) | 2013-01-17 | — | — | US | disclosed |
| US-20130018052-A1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS | SK CHEMICALS CO., LTD. (KR) | 2013-01-17 | — | — | US | disclosed |
| WO-2013009140-A2 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS | SK CHEMICALS CO., LTD. (KR) | 2013-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10155763-B2 | 2-pyridyl substituted imidazoles as ALK5 and/or ALK4 inhibitors | ACVR1, ACVRL1, ALK | TGFBR1 5/4885MAPK14 646/4885MTOR 754/4885 |
| US-20130018052-A1 | 2-PYRIDYL SUBSTITUTED IMIDAZOLES AS ALK5 AND/OR ALK4 INHIBITORS | ACVR1, ACVRL1, ALK | TGFBR1 5/4885MAPK14 646/4885MTOR 754/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.